HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed 25 enrolled Zhongda Hospital

NaSingle-groupOpen-labelTreatment

To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.

Evaluation	Drug	Modality	Dose	Route
Subject	Donafenib	Small molecule	0.2 unknown	Oral
Subject	Gemcitabine	Small molecule	1000 mg/m2	Other
Subject	Oxaliplatin	Small molecule	85 mg/m2	Other
Subject	Oxaliplatin	Small molecule	130 mg/m2	Other
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous